skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8838

Aliskiren and valsartan combination therapy for the management of hypertension

Review

(2885) Views  (1188) Full article downloads

Authors: Benjamin J Epstein

Published Date August 2010 Volume 2010:6 Pages 711 - 722
DOI: http://dx.doi.org/10.2147/VHRM.S8175

Benjamin J Epstein
Departments of Pharmacotherapy and Translational Research and Medicine, Colleges of Pharmacy and Medicine, University of Florida, Gainesville, Florida, USA and East Coast Institute for Research, Jacksonville, Florida, USA

Abstract: Combination therapy is necessary for most patients with hypertension, and agents that inhibit the renin-angiotensin-aldosterone system (RAAS) are mainstays in hypertension management, especially for patients at high cardiovascular and renal risk. Single blockade of the RAAS with an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) confers some cardiorenal protection; however, these agents do not extinguish the RAAS as evidenced by a reactive increase in plasma renin activity (PRA), a cardiovascular risk marker, and incomplete cardiorenal protection. Dual blockade with an ACE inhibitor and an ARB offers no additional benefit in patients with hypertension and normal renal and left ventricular function. Indeed, PRA increases synergistically with dual blockade. Aliskiren, the first direct renin inhibitor (DRI) to become available has provided an opportunity to study the merit of DRI/ARB combination treatment. By blocking the first and rate-limiting step in the RAAS, aliskiren reduces PRA by at least 70% and buffers the compensatory increase in PRA observed with ACE inhibitors and ARBs. The combination of a DRI and an ARB or an ACE inhibitor is an effective approach for lowering blood pressure; available data indicate that such combinations favorably affect proteinuria, left ventricular mass index, and brain natriuretic peptide in patients with albuminuria, left ventricular hypertrophy, and heart failure, respectively. Ongoing outcome studies will clarify the role of aliskiren and aliskiren-based combination RAAS blockade in patients with hypertension and those at high cardiorenal risk.

Keywords: aliskiren, valsartan, single-pill combination, hypertension, renin-angiotensin-aldosterone system, plasma renin activity







Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting
Valsartan addition to amlodipine is more effective than losartan addition in hypertensive patients inadequately controlled by amlodipine
New standards in hypertension and cardiovascular risk management: focus on telmisartan
Role of valsartan, amlodipine and hydrochlorothiazide fixed combination in blood pressure control: an update
Triple combination therapy with amlodipine, valsartan, and hydrochlorothiazide vs dual combination therapy with amlodipine and hydrochlorothiazide for stage 2 hypertensive patients
Clinical utility of rosuvastatin and other statins for cardiovascular risk reduction among the elderly
Effect of vascular burden as measured by vascular indexes upon vascular dementia: a matched case-control study
Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy?
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University